SCHEMBL11272093

SCHEMBL11272093

CC(=O)SCCC1SC[C@@H](C(=O)O)N1C(=O)CCSSCC(COC(=O)C(C)(C)C)(COC(=O)C(C)(C)C)C(=O)N1C(CCSC(C)=O)SC[C@H]1C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11188785 0.83 KMT2A (0.37) —
SCHEMBL11189826 0.81 — —
SCHEMBL11196508 0.75 ACE (0.55) —
SCHEMBL11188904 0.75 GAA (0.51) —
SCHEMBL11266045 0.72 ACE (0.41) —
SCHEMBL11192009 0.70 KMT2A (0.57) —
SCHEMBL11272933 0.67 ACE (0.35) —
SCHEMBL11261862 0.61 ACE (0.60) —
SCHEMBL11247800 0.61 — —
SCHEMBL11189446 0.59 GAA (0.44) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4347371-A HYPERTENSIVE AGENTS; ANTIDIABETIC AGENTS; VISION DEFECTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 1982-08-31 — — US disclosed
Send feedback